English Wikipedia @ Freddythechick

Teneliximab

Monoclonal antibody

This is the current revision of this page, as edited by imported>Citation bot at 19:38, 2 September 2023 (Alter: title, template type. Add: chapter-url, series, chapter. Removed or converted URL. Removed parameters. Some additions/deletions were parameter name changes. | Use this bot. Report bugs. | #UCB_CommandLine). The present address (URL) is a permanent link to this version.

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Teneliximab is a chimeric monoclonal antibody[1] binding to the immune stimulatory protein CD40.[2] As of 2009, it has not entered clinical trials.[2]

Teneliximab
Monoclonal antibody
TypeWhole antibody
SourceChimeric (mouse/human)
TargetCD40
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
 ☒NcheckY (what is this?)  (verify)

References

  1. ^ International Nonproprietary Names For Pharmaceutical Substances
  2. ^ 2.0 2.1 Law CL, Grewal IS (2009). "Therapeutic Interventions Targeting CD40L (CD154) and CD40: The Opportunities and Challenges". Therapeutic Targets of the TNF Superfamily. Advances in Experimental Medicine and Biology. Vol. 647. New York, N.Y.: Springer Science+Business Media. pp. 8–36. doi:10.1007/978-0-387-89520-8_2. ISBN 978-0-387-89520-8. PMID 19760064.


 

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

 

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://enwiki.freddythechick.net/index.php?title=Teneliximab&oldid=12479987"